MedTrace Logo

A Study of Fisetin to Treat Carpal Tunnel Syndrome

NCT05416515 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-12-24

Study results available
· View outcomes & findings →

Summary

This research study is being conducted to investigate the safety and effectiveness of the drug Fisetin for mild or moderate carpal tunnel syndrome (CTS).

Conditions

  • Carpal Tunnel Syndrome

Interventions

DRUG

Fisetin

100 mg capsules orally for 2 consecutive days and, after 1 month, another 2 consecutive days

Sponsors & Collaborators

  • Peter C. Amadio, M.D.

    lead OTHER

Principal Investigators

  • Peter C Amadio, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-09
Primary Completion
2024-12-31
Completion
2025-01-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05416515 on ClinicalTrials.gov